Junshi Biosciences: Juntuo Biosciences plans to increase capital by 80 million yuan in Beijing Shali.

Junshi Biopharma announced that its wholly-owned subsidiary, Junuo Biopharma, plans to subscribe for 1,280,623 shares of Beijing Gravel Biopharma Co., Ltd. with 80 million yuan. After the capital increase, Junshi Biopharma and Junuo Biopharma will collectively hold 5.1105% equity in Beijing Gravel. Shareholder Shanghai Tanying, who directly holds more than 5% of the company's shares, intends to participate in this capital increase by subscribing for 640,311 shares of Beijing Gravel with 40 million yuan. This transaction is considered a related party joint investment and constitutes a related party transaction. The target company is an innovative pharmaceutical company focused on tumor immunotherapy cell treatment, with a research and development pipeline represented by tumor-infiltrating lymphocyte drugs.